Inogen Stock Gains Following Solid Preliminary Q4 Revenues
INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device
INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Inogen (INGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Inogen (INGN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.
Inogen, Inc. (INGN) Q3 2024 Earnings Call Transcript
Call Start: 17:00 January 1, 0000 5:26 PM ET Inogen, Inc. (NASDAQ:INGN ) Q3 2024 Earnings Conference Call November 7, 2024, 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Mike Matson - Needham Operator Welcome to Inogen's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Inogen (INGN) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Inogen (INGN) Reports Q3 Loss, Tops Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $1.97 per share a year ago.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Inogen Stock Rises 47% in 6 Months: What's Driving the Rally?
INGN shows impressive momentum, driven by strong sales growth, an expanding product portfolio and significant advancements in portable oxygen technology.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for the INGN stock.
Inogen (INGN) Rises 127% Year to Date: What's Driving the Stock?
Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock.
